From:
`To:
`Cc:
`
`Subject:
`Date:
`
`Trials
`Ferguson, Brian; Trials
`Holland, Elizabeth J.; James, William G.; Cipriano, Linnea P; Weinger, Joshua; Desai, Anish; Weiswasser,
`Elizabeth; Pepe, Christopher; Kennedy, Natalie; Patel, Priyata; Gesior, Andrew
`RE: IPR2020-01318: Regeneron v. Novartis; Motion to Terminate Proceedings
`Tuesday, November 24, 2020 9:11:35 AM
`
`Counsel:
`
`The panel has reviewed Petitioner’s request to file a motion to terminate the proceedings in IPR2020-
`01318 pursuant to 37 C.F.R. §§ 42.5(a), 42.71(a). The panel authorizes the request without the need for a
`conference call. Petitioner is authorized to file an “Unopposed Motion to Dismiss the Petition and to
`Terminate the Proceeding” (37 C.F.R. § 42.72) by December 8, 2020. Petitioner must indicate in the
`motion whether it is unopposed and what impact, if any, the termination has on the remaining petition in
`IPR2020-01317.
`
`Regards,
`
`Andrew Kellogg,
`Supervisory Paralegal
`Patent Trial and Appeal Board
`USPTO
`andrew.kellogg@uspto.gov
`(571)272-7822
`
`
`
`From: Ferguson, Brian <brian.ferguson@weil.com>
`Sent: Friday, November 20, 2020 3:52 PM
`To: Trials <Trials@USPTO.GOV>
`Cc: Holland, Elizabeth J. <EHolland@goodwinlaw.com>; James, William G.
`<WJames@goodwinlaw.com>; Cipriano, Linnea P <LCipriano@goodwinlaw.com>; Weinger, Joshua
`<JWeinger@goodwinlaw.com>; Desai, Anish <anish.desai@weil.com>; Weiswasser, Elizabeth
`<Elizabeth.Weiswasser@weil.com>; Pepe, Christopher <Christopher.Pepe@weil.com>; Kennedy,
`Natalie <Natalie.Kennedy@weil.com>; Patel, Priyata <Priyata.Patel@weil.com>; Gesior, Andrew
`<Andrew.Gesior@weil.com>
`Subject: IPR2020-01318: Regeneron v. Novartis; Motion to Terminate Proceedings
`
`
`IPR2020-01318
`Patent 9,220,631 B2
`
`Dear Trial Board:
`
`We are counsel of record for Petitioner Regeneron Pharmaceuticals in the above-identified IPR.
`Petitioner requests permission to file a motion to terminate the proceedings in IPR2020-01318
`pursuant to 37 C.F.R. §§ 42.5(a), 42.71(a). Because the Board has not yet determined whether to
`institute a trial, dismissal of the Petition and termination of the proceedings will preserve the
`resources of the Board and the parties, and will promote efficiency as contemplated by 37 C.F.R. §
`42.1(b). Co-pending IPR2020-01317, directed to the same patent, will remain pending for the
`
`Regeneron Exhibit 1066.001
`Regeneron v. Novartis
`IPR2020-01317
`
`

`

`Board’s consideration.
`
`We have conferred with counsel for Patent Owner, copied on this email, and Patent Owner does not
`oppose Petitioner’s contemplated motion. If necessary, the parties are available for a call with the
`Board on the following dates and times:
`
`Monday, November 23 after 2 pm Eastern
`Tuesday, November 24 after 1 pm Eastern
`Wednesday, November 25 before 11 am Eastern.
`
`Respectfully submitted,
`
`Brian Ferguson
`Backup Counsel for Petitioner
`
`
`
`Brian E. Ferguson
`Co-Head, Patent Litigation Group
`
`Weil, Gotshal & Manges LLP
`2001 M Street NW, Suite 600
`Washington, DC 20036
`brian.ferguson@weil.com
`+1 202 682 7516 Direct
`+1 301 801 8870 iPhone
`
`
`
`
`The information contained in this email message is intended only for use of the individual or entity named
`above. If the reader of this message is not the intended recipient, or the employee or agent responsible to
`deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying
`of this communication is strictly prohibited. If you have received this communication in error, please
`immediately notify us by email, postmaster@weil.com, and destroy the original message. Thank you.
`
`Regeneron Exhibit 1066.002
`Regeneron v. Novartis
`IPR2020-01317
`
`